A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. - Concepedia

Concepedia

Publication | Closed Access

A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease.

47

Citations

0

References

2012

Year

Hailing Hsu, Sanjay D. Khare, Frances Lee, Kent Miner, Yiling Hu, Marina Stolina, Nessa Hawkins, Qing Chen, Shu-Yin Joanne Ho, Hosung Min,

Abstract

AMG623 is a novel modality of BAFF antagonist. AMG623 is a potential therapeutic agent for the treatment of SLE, rheumatoid arthritis, and other B-cell-mediated autoimmune diseases.